GLAUKOS Corp cotiza a 165.50 USD y tiene una capitalización bursátil de $9.8B. En los últimos 12 meses ha facturado $613M con un margen de flujo de caja libre del -4.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle gla…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.14 | $-0.18 | $-0.28 |
| Estimado | $-0.09 | $-0.21 | $-0.28 | $-0.20 |
| Sorpresa | — | +33.3% | +35.7% | -40.0% |
| Métrica | GKOS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 55.7% | 57.0% | -1.3% |
| Operating Margin | -39.3% | -38.6% | -0.7% |
| Net Margin | -37.0% | -33.6% | -3.4% |
| FCF Margin | -4.4% | -13.9% | +9.4% |
| ROE | -28.6% | -40.4% | +11.8% |
| ROA | -21.0% | -32.0% | +11.0% |
| Current Ratio | 4.69 | 2.84 | +1.85 |
| Debt / Equity | — | 0.28 | — |